Gazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals.
The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug market for atopic dermatitis in dogs. The value of this market in 2019 was estimated at approximately USD 900 million. However, it can be expected that this value is underestimated – the two most important atopy products from the portfolio of the veterinary giant – Zoetis, i.e. Cytopoint and Apoquel, generated a combined revenue of over $ 700 million in 2019.
Everything indicates that the drug market for atopic dermatitis in dogs, as in humans, will develop dynamically, as the problem of atopy continues to worsen. This is due to the increasing number of allergens in the air and in the food of our pets. “
More on the portal: https://www.wroclaw.pl/biznes/bioceltix-leki-biologiczne
Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...
ArticleForbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...
ArticleAccording to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...
ArticleGazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...
ArticleWe create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...
ArticleWe create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from ...
Read full2019? It’s been a good year for Bioceltix. A victory in the Start-Up Challenge coupled with participation in accelerator programs as well as ...
Read fullMamstartup: Gallant has developed a non invasive method for retrieving stem cells which can be used to treat various ailments – from torn ...
Read full
